Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redcare Pharmacy NV is a company based in the Netherlands that retails pharmaceutical products online. The Company focuses on non-prescription medication (OTC), as well as on pharmacy-related beauty and personal care (BPC) products. The Company is active in Belgium, Spain, Italy, France, Austria, the Netherlands and Germany.

  • Revenue in EUR (TTM)1.99bn
  • Net income in EUR-9.62m
  • Incorporated2015
  • Employees2.08k
More ▼

Institutional shareholders

24.56%Per cent of shares held by top holders
HolderShares% Held
DWS Investment GmbHas of 03 May 20241.04m5.09%
Capital Research & Management Co. (World Investors)as of 31 Dec 2023977.84k4.81%
T. Rowe Price International Ltd.as of 06 Dec 2023597.81k2.94%
Allianz Global Investors GmbHas of 17 May 2023551.67k2.71%
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024480.52k2.36%
Union Investment Privatfonds GmbHas of 30 Sep 2022407.90k2.01%
The Vanguard Group, Inc.as of 05 Apr 2024294.49k1.45%
Norges Bank Investment Managementas of 31 Dec 2023284.58k1.40%
BlackRock Fund Advisorsas of 04 Apr 2024185.88k0.91%
Swedbank Robur Fonder ABas of 29 Feb 2024180.00k0.89%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.